Q-omics provides the consensus-scored GLUD1P2 profile across patient tissues and cancer cell-line models. GLUD1P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GLUD1P2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, GLUD1P2 RNA expression shows 15,958 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where GLUD1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLUD1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLUD1P2 survival associations across molecular data types. GLUD1P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLUD1P2 RNA expression–survival associations across cancer types. High GLUD1P2 expression shows unfavorable associations in ACC, but favorable associations in UVM, LGG, KIRP, UCS and THCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GLUD1P2 RNA expression.
This table summarizes GLUD1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GLUD1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLUD1P2 shows lower tumor expression in KICH, THCA, BRCA and COAD and higher tumor expression in KIRC and LIHC. The KICH box plot shows higher GLUD1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.946, t-test p < 0.001).
This table shows molecular features associated with GLUD1P2 in patient tissues and cancer cell lines. In patient samples, GLUD1P2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GLUD1P2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS.
